This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Potassium aminobenzoate oral formulations

Updated 2 Feb 2023 | Vitamin B group


Oral formulations of potassium aminobenzoate.

Drugs List

  • POTABA 3g/sachet sachets
  • potassium para-aminobenzoate 3g/sachet oral powder
  • Therapeutic Indications


    Peyronie's disease



    One sachet of 3g four times daily.


    For oral administration with food. One sachet should be dissolved in cold water or fruit juice.


    Children under 18 years
    Renal impairment
    Severe hepatic impairment

    Precautions and Warnings

    Prolonged fasting
    Anorexia nervosa
    Cardiovascular disorder
    Diabetes mellitus

    Advise ability to drive/operate machinery may be affected by side effects
    Correct hyperkalaemia before starting treatment
    Consider discontinuing treatment until hyperkalaemia has been corrected
    Monitor closely for skin reactions
    Monitor hepatic function regularly
    Monitor serum potassium periodically
    Increased risk of hypoglycaemia with low food intake
    Discontinue and do not restart if severe cutaneous adverse reactions occur
    Discontinue permanently if severe hypersensitivity reactions occur
    Interrupt treatment if patient is not eating enough
    Advise patients of the warning signs of hypoglycaemia

    Before initiating treatment an anamnestic survey of pre-existing hyperkalaemia risk factors including an initial serum potassium determination should be performed for all patients. Serum potassium should be measured at least monthly or at closer intervals (depending on risk assessment and monitoring requirements due to other risk factors) in patients with an increased risk of hyperkalaemia. Patients with an increased initial serum potassium level, the underlying cause should be identified and serum potassium levels should be corrected before the start of treatment. For these patients, monitoring after the start of treatment should also be performed monthly until long-term normal serum potassium levels are established. Monitoring is recommended at least quarterly.

    Pregnancy and Lactation


    Potassium aminobenzoate is contraindicated during pregnancy.

    The manufacturer does not recommend using potassium aminobenzoate during pregnancy. There is limited data from the use of potassium aminobenzoate in pregnancy.


    Potassium aminobenzoate is contraindicated during breastfeeding.

    The manufacturer does not recommend using potassium aminobenzoate during breastfeeding. It is unknown whether potassium aminobenzoate is excreted in human breast milk. A risk to the newborns/infants cannot be excluded.

    Side Effects

    Drug rash with eosinophilia and systemic symptoms (DRESS)
    Drug-induced liver injury
    Elevation of liver enzymes
    Hepatic failure
    Hypersensitivity reactions
    Severe cutaneous adverse reactions
    Stomach discomfort


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: July 2021

    Reference Sources

    Summary of Product Characteristics: Potaba 3g Powder Sachets. Neon Healthcare Limited. Revised May 2021.

    NICE Evidence Services Available at: Last accessed: 23 July 2021

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.